Adams “edible film” OTCs
This article was originally published in The Tan Sheet
Adams Respiratory Therapeutics will develop oral thin-film drug delivery OTC and pharmaceutical respiratory products under a licensing agreement with drug delivery firm MonoSol Rx, the company announces March 27. Under the deal, Adams receives an exclusive, royalty-bearing non-transferable license from MonoSol to develop and market two or more respiratory products in North America. Under a separate agreement, MonoSol will manufacture and supply the finished products. MonoSol will complete product development, while Adams will perform all clinical development, regulatory submissions and commercial operations. Financial terms of the deal were not disclosed, but Adams notes MonoSol will receive payments in exchange for completing pre-defined development milestones. Leiner launched several OTC drug and dietary supplement products in orally dissolving strips in 2005 under a deal with MonoSol (1"The Tan Sheet" Aug. 15, 2005, p. 8)...
You may also be interested in...
Leiner will launch at least three new OTC drug and dietary supplement products in orally dissolving strip formulations later this year under a licensing agreement with MonoSol Rx
Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.
Acquiring Clarion Brands from Swander Pace, Bridges Consumer Healthcare adds portfolio of OTC and supplement brands for symptoms including tinnitus, urinary pain relief and excessive sweating.